University of Hertfordshire


  • 907170

    Final published version, 633 KB, PDF document

  • Munya Dimairo
  • Jonathan Boote
  • Steven A. Julious
  • Jon Nicholl
  • Susan Todd
View graph of relations
Original languageEnglish
Article number430
Number of pages16
Publication statusPublished - 28 Sep 2015


Despite the promising benefits of adaptive designs (ADs), their routine use, especially in confirmatory trials, is lagging behind the prominence given to them in the statistical literature. Much of the previous research to understand barriers and potential facilitators to the use of ADs has been driven from a pharmaceutical drug
development perspective, with little focus on trials in the public sector. In this paper, we explore key stakeholders’ experiences, perceptions and views on barriers and facilitators to the use of ADs in publicly funded confirmatory trials


Date of Acceptance: 14/09/2015. © 2015 Dimairo et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated

ID: 8754413